



# IRA e-bulletin

Newsletter For Health Professionals in Rheumatology

From the  
Editor's  
Desk



Latest  
Research



Expert  
Opinion



Conference  
Calendar



IRA  
Matters



News from  
EULAR 2013



Do You  
Know?



## News from EULAR 2013

### Oral Apremilast effective in Psoriatic Arthritis

The investigational oral drug apremilast demonstrate clinical improvement in the signs and symptoms of psoriatic arthritis, physical function, and skin improvement at 52 weeks, according to updated results from the PALACE-1 trial.

PALACE-1, is a phase 3, multicenter, double-blind, placebo-controlled, parallel-group study that enrolled 504 patients with active psoriatic arthritis despite treatment with DMARDs and biologics.

Apremilast is an inhibitor of phosphodiesterase-4 that modulates a network of pro- and anti-inflammatory intracellular mediators.

### Tocilizumab is effective in polyarticular juvenile arthritis

Children with polyarticular juvenile idiopathic arthritis treated with tocilizumab achieved high response rates with sustained improvement in the phase 3 CHERISH trial.

CHERISH is a 3-year international trial conducted at 58 centers in 15 countries and overseen by the Pediatric Rheumatology Collaborative Study Group and the Pediatric Rheumatology International Trials Organization.

The study involved 188 children with active polyarticular juvenile arthritis for at least 6 months and a failed response to methotrexate.